REGEN-COV Monoclonal Antibody Treatment Available

IV Infusion or Subcutaneous Injections

The U.S. Food and Drug Administration revised the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) authorizing REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.

REGEN-COV is not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus — only after exposure to the virus.

REGEN-COV also remains authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19. FDA has authorized three vaccines to prevent COVID-19 and serious clinical outcomes caused by COVID-19, including hospitalization and death. FDA urges you to get vaccinated, if you are eligible.

COVID-19 services offered at Body Lounge Park Cities:
* Monoclonal Antibody Treatments
* COVID-19 Testing
* COVID-19 Antibody Testing
* Vaccines: Moderna and Pfizer
@bodyloungeparkcities
@bodyloungewellness

Font Resize
Contrast
Call Us Text Us